IndoVac

Vaccine description
Target	SARS-CoV-2
Vaccine type	Protein subunit
Clinical data
Trade names	IndoVac
Routes of administration	Intramuscular

Part of a series on the
COVID-19 pandemic
COVID-19 (disease) SARS-CoV-2 (virus) Cases Deaths
Timeline 2019 2020 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November responses December responses 2021 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November responses December responses 2022 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November December 2023 2024
Locations By country and territory Africa Antarctica Asia Europe North America Oceania South America By conveyance Cruise ships Naval ships
International response Endemic phase Evacuations Face masks International aid Origin Lockdowns by country Misinformation by governments Fake treatments Social distancing Software Travel United Nations World Health Organization WTO IP waiver Undercounting of deaths COVID-19 apps Zero-COVID National responses Africa China European Union Germany Ghana India Ireland Netherlands New Zealand Nigeria Philippines Russia Sweden UK government US federal government Vietnam
Medical response Disease testing Breathalyzer Development Drug development Drug repurposing Public health mitigation Vaccines History Research VITT Deployment Authorizations Operation Warp Speed Misinformation and hesitancy US Vaccine card Vaccine passports Current vaccines CoronaVac Covaxin Convidecia Janssen Medigen Moderna Novavax Oxford–AstraZeneca Pfizer–BioNTech Sinopharm BIBP Sputnik V
Variants Variants of concern Alpha Beta Gamma Delta Omicron Other variants Epsilon Zeta Eta Theta Iota Kappa Lambda Mu Cluster 5 Lineage B.1.617
Economic impact and recession Arts and culture Aviation Cannabis Cinema films Disney Fashion Financial markets Food industry Food security Journalism Music Performing arts Retail Shipping Television US sportscasting programs Tourism Video games By country Canada India Ireland Malaysia New Zealand Russia UK US By sport Association football Baseball Basketball Combat sports Cricket Disc golf Gaelic games Gridiron football Ice hockey Motorsport Rugby league
Impacts Animals Alzheimer's disease patients Black people Crime Death rates by country Disability Domestic violence Emergency evacuations Education Female Environment Hospitals Language LGBT community Long-term care Media coverage Mental health symptoms Migration Military Notable deaths Other health issues Politics diplomacy Popular culture Protests Pregnancy Prisons Religion Catholic Church Hajj Science and technology Social media Strikes Suicides Telehealth Xenophobia and racism Society Ireland Malaysia New Zealand Russia UK US
COVID-19 portal
v t e

IndoVac is a recombinant protein subunit COVID-19 vaccine,^[1][2] developed by Indonesian pharmaceutical company Bio Farma and Baylor College of Medicine in Houston, Texas.^[1][2] It is the world's first officially halal certified COVID-19 vaccine,^[3] but the most popular existing vaccines had already been widely endorsed as Halal by various Islamic groups.^[4][5] The vaccine was officially launched by President Joko Widodo on 13 October 2022.^[6]

Technology

The vaccine consists of an active yeast-based receptor binding domain (RBD) of the SARS‑CoV‑2 spike protein.^[7] With no animal cells or products being used in its production,^[3] IndoVac received its halal certificate from the Halal Product Assurance Organizing Body of the Ministry of Religious Affairs on 29 July 2022.^[8]

Manufacturing

In October 2022, President Joko Widodo announced that Bio Farma will produce up to 20 million doses of the vaccine for the initial first phase of production in the same year. The production capacity will be increased to 40 million doses in 2023.^[1]